Phase III study of abicipar in patients with Diabetic macular edema (DME)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 06 Apr 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abicipar pegol (Primary)
Indications Diabetic macular oedema
Focus Therapeutic Use
Sponsors AbbVie; Allergan

Most Recent Events

09 May 2019 According to a Molecular Partners AG media release, Allergan plans to launch this trial in 2020.
07 Feb 2019 According to a Molecular Partners AG media release, Allergan intends to initiate this study in H2 2019.
08 Feb 2018 According to a Molecular Partners AG media release, company expects to initiate this trial in H2 2018.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight